Astellas Pharma Inc.’s subsidiaries Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells Inc. have entered into a research collaboration with Osaka University to develop a pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease.